Legacy Capital Wealth Partners LLC Has $675,000 Position in Cencora, Inc. $COR

Legacy Capital Wealth Partners LLC cut its position in Cencora, Inc. (NYSE:COR) by 12.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,251 shares of the company’s stock after selling 309 shares during the quarter. Legacy Capital Wealth Partners LLC’s holdings in Cencora were worth $675,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in COR. Atlantic Edge Private Wealth Management LLC boosted its position in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the period. Grove Bank & Trust increased its position in Cencora by 4.3% in the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the period. Quadcap Wealth Management LLC raised its stake in shares of Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after acquiring an additional 36 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its holdings in shares of Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after purchasing an additional 38 shares during the period. Finally, Monument Capital Management lifted its holdings in shares of Cencora by 2.4% during the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock worth $491,000 after purchasing an additional 38 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Up 0.1%

Shares of NYSE:COR opened at $368.93 on Friday. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The business’s 50-day moving average is $335.71 and its 200-day moving average is $307.63. The company has a market capitalization of $71.53 billion, a price-to-earnings ratio of 37.96, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be paid a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This represents a 11.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

COR has been the subject of several analyst reports. Wells Fargo & Company raised their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research note on Tuesday. Evercore ISI set a $400.00 price objective on Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Robert W. Baird upped their target price on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, TD Cowen raised their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.